Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing.
Yao JiangAndrew D SouthamSandro TrovaFlavio BekeBader AlhazmiThomas FrancisAnshul RadotraAlessandro di MaioMark T DraysonChris M BunceFarhat L KhanimPublished in: British journal of cancer (2021)
Given the good safety data of low-dose BaP in elderly/relapsed/refractory AML patients, and that VAL alone is well-tolerated, we propose VBaP as a novel therapeutic combination for AML.
Keyphrases
- acute myeloid leukemia
- low dose
- reactive oxygen species
- end stage renal disease
- induced apoptosis
- newly diagnosed
- ejection fraction
- allogeneic hematopoietic stem cell transplantation
- oxidative stress
- chronic kidney disease
- acute lymphoblastic leukemia
- peritoneal dialysis
- bone marrow
- diffuse large b cell lymphoma
- cell cycle arrest
- dendritic cells
- machine learning
- electronic health record
- middle aged
- respiratory failure
- intensive care unit
- patient reported outcomes
- immune response
- aortic dissection
- extracorporeal membrane oxygenation
- pi k akt